Related Experiment Video
Updated: Mar 1, 2026
07:41
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
9.7K
RAS pathway biomarkers for breast cancer prognosis
Lauren L Siewertsz van Reesema1, Michael P Lee1, Vasilena Zheleva2
1Eastern Virginia Medical School, Norfolk, VA 23507, USA.
Clinical Laboratory International
|June 6, 2017
Summary
RAS pathway activation is understudied in metastatic breast cancer. Identifying RAS pathway biomarkers can help stratify patients and guide therapies for better treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Metastatic breast cancer (MBC) is a complex and aggressive disease with limited curative options.
- RAS pathway activation is a poorly understood mechanism in MBC development and progression.
- Epidermal growth factor receptor (EGFR)/RAS pathway activation is frequently observed in MBC and associated with poor prognosis.
Purpose of the Study:
- To investigate the role of RAS pathway activation in metastatic breast cancer.
- To identify prognostic biomarkers within the RAS pathway for MBC.
- To explore the potential of RAS pathway biomarkers in guiding therapeutic strategies.
Main Methods:
- Analysis of RAS pathway signaling in MBC patient samples.
- Biomarker discovery using molecular profiling techniques.
- Correlation of biomarker expression with clinical outcomes and treatment response.
Main Results:
- RAS pathway activation is a significant factor in MBC heterogeneity and evolution.
- Specific RAS pathway biomarkers are identified with prognostic value.
- These biomarkers can distinguish tumor clones resistant to current therapies.
Conclusions:
- RAS pathway activation represents a critical, yet understudied, therapeutic target in MBC.
- Prognostic RAS pathway biomarkers offer a novel approach for patient stratification.
- Targeting the RAS pathway holds promise for developing more effective therapies for metastatic breast cancer.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
01:22PI3K/mTOR/AKT Signaling Pathway
5.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.9K
02:54Canonical Wnt Signaling Pathway
10.8K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
10.8K
02:07Tumor Progression
7.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.6K